ReviewInfluenza and other respiratory viruses2013
Influenza prevention and treatment in transplant recipients and immunocompromised hosts.
Review in Influenza and other respiratory viruses, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 63 citations in OpenAlex.
- Influenza.Nature reviews. Disease primers · 2026Review
- Use of baloxavir as adjunctive antiviral therapy to neuraminidase inhibitors in severely immunocompromised individuals infected with influenza.Antimicrobial agents and chemotherapy · 2026Article
- Influenza Antivirals for Prevention and Treatment in Immunocompromised People.The Journal of infectious diseases · 2025Review
- A Retrospective Test-Negative Case-Control Study to Evaluate Influenza Vaccine Effectiveness in Preventing Influenza Among Immunocompromised Adults With a Solid Organ Transplant.Transplant international : official journal of the European Society for Organ Transplantation · 2025Article
- Pneumonia in Transplant Recipients: A Comprehensive Review of Diagnosis and Management.Cureus · 2024Review
- Impact of Respiratory Viral Infections in Transplant Recipients.Journal of the Pediatric Infectious Diseases Society · 2024Review
- Vaccine-Preventable Illness Leads to Adverse Outcomes in Liver Transplant Recipients.Digestive diseases and sciences · 2024Article
- Phylogenetic analysis of HA and NA genes of influenza A viruses in immunosuppressed inpatients in Beijing during the 2018-2020 influenza seasons.Virology journal · 2023Article
- Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19.Blood cancer discovery · 2022Article
- Clinical characteristics, risk factors and antiviral treatments of influenza in immunosuppressed inpatients in Beijing during the 2015-2020 influenza seasons.Virology journal · 2022Article
- Improving the Outcomes of Immunocompromised Patients With Coronavirus Disease 2019.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- Monoclonal Antibody Therapy Protects Pharmacologically Immunosuppressed Mice from Lethal Infection with Influenza B Virus.Antimicrobial agents and chemotherapy · 2020Article
- FluA-p score: a novel prediction rule for mortality in influenza A-related pneumonia patients.Respiratory research · 2020Article
- Optimizing T-705 (favipiravir) treatment of severe influenza B virus infection in the immunocompromised mouse model.The Journal of antimicrobial chemotherapy · 2019Article
- A pharmacologically immunosuppressed mouse model for assessing influenza B virus pathogenicity and oseltamivir treatment.Antiviral research · 2017Article
- Pathogenicity and peramivir efficacy in immunocompromised murine models of influenza B virus infection.Scientific reports · 2017Article
- Development of oseltamivir and zanamivir resistance in influenza A(H1N1)pdm09 virus, Denmark, 2014.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2017Article
- A Review of Clinical Influenza A and B Infections With Reduced Susceptibility to Both Oseltamivir and Zanamivir.Open forum infectious diseases · 2017Review
- Travellers and influenza: risks and prevention.Journal of travel medicine · 2017Review
- Pharmacological Characterization of the Spectrum of Antiviral Activity and Genetic Barrier to Drug Resistance of M2-S31N Channel Blockers.Molecular pharmacology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The host immune response is critical for the control and clearance of influenza virus after initial infection. Unfortunately, key components of the innate and adaptive responses to influenza are compromised in solid organ and hematopoietic stem cell transplant recipients. As a result, influenza in these key patient populations is associated with prolonged viral shedding, more frequent complications, including bacterial and fungal superinfections and rejection, and increased mortality. While vaccine is the critical prophylaxis strategy in other populations, response rates are diminished, particularly early post-transplant, among immunocompromised patients. Prospective data suggest that antiviral prophylaxis represents an effective and safe alternative to vaccine in patients who would be predicted to have poor responses to influenza vaccine. While there have not been randomized, controlled studies of antiviral therapy completed in solid organ or hematopoietic stem cell patient populations, observational data suggest that early therapy is associated with reduced rates of progression to lower airway involvement, morbidity, and mortality. Further studies are needed to define the optimal regimen, dose, duration, and endpoint to define successful treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.